Pioglitazone modulates the proliferation and apoptosis of vascular smooth muscle cells via peroxisome proliferators-activated receptor-gamma

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Wan, Jing ^a   Xiao, Zhichao ^b   Chao, Shengping ^a   Xiong, Shixi ^a   Gan, Xuedong ^a   Qiu, Xuguang ^b   Xu, Chang ^b   Ma, Yexin ^b   Tu, Xin ^c  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Caspase; Cyclins; Peroxisome proliferators activated receptor gamma; Thiazolidinedione

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CYCLIN B1; CYCLIN D1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; SMALL INTERFERING RNA;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING;

EID: 84908108254     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-101     Document Type: Article

References (44)

1. Kinetics of vein graft hyperplasia: association with tangential stress. Zwolak RM, Adams MC, Clowes AW, J Vasc Surg 1987 5 1 126 136 10.1016/0741-5214(87)90203-5 3795379
2. Cell biology of atherosclerosis. Ross R, Annu Rev Physiol 1995 57 791 804 10.1146/annurev.ph.57.030195.004043 7778883
3. Ibuprofen inhibits migration and proliferation of human coronary artery smooth muscle cells by inducing a differentiated phenotype: role of peroxisome proliferator-activated receptor γ Dannoura A, Giraldo A, Pereira I, Gibbins JM, Dash PR, Bicknell KA, Brooks G, J Pharm Pharmacol 2014 10 112 2301 2314
4. Caffeic acid phenethyl ester inhibits proliferation and migration, and induces apoptosis in platelet-derived growth factor-BB-stimulated human coronary smooth muscle cells. Ho HC, Chang HC, Ting CT, Kuo CY, Yang VC, J Vasc Res 2012 49 1 24 32 10.1159/000329819 21986482
5. Matsumura YPathological importance of the endothelin-1/ET (B) receptor system on vascular diseases. Kitada K, Ohkita M, Cardiol Res Pract 2012 1212 731 738
6. Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro. Brisset AC, Hao H, Camenzind E, Bacchetta M, Geinoz A, Sanchez JC, Chaponnier C, Gabbiani G, Bochaton-Piallat ML, Circ Res 2007 100 7 1055 1062 10.1161/01.RES.0000262654.84810.6c 17347479
7. Peroxisome proliferator-activated receptor gamma and metabolic disease. Willson TM, Lambert MH, Kliewer SA, Annu Rev Biochem 2001 70 341 367 10.1146/annurev.biochem.70.1.341 11395411
8. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Rangwala SM, Lazar MA, Trends Pharmacol Sci 2004 25 6 331 336 10.1016/j.tips.2004.03.012 15165749
9. 3 T3-L1 adipocyte apoptosis induced by thiazolidinediones is peroxisome proliferator-activated receptor-gamma-dependent and mediated by the caspase-3-dependent apoptotic pathway. Xiao Y, Yuan T, Yao W, Liao K, FEBS J 2010 277 3 687 696 10.1111/j.1742-4658.2009.07514.x 20050918
10. Inhibition of reactive oxygen species/extracellular signal-regulated kinases pathway by pioglitazone attenuates advanced glycation end products-induced proliferation of vascular smooth muscle cells in rats. Yuan X, Zhang Z, Gong K, Zhao P, Qin J, Liu N, Biol Pharm Bull 2011 34 5 618 623 10.1248/bpb.34.618 21532147
11. Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway. Ruiz E, Redondo S, Gordillo-Moscoso A, Tejerina T, J Pharmacol Exp Ther 2007 321 2 431 438 10.1124/jpet.106.114934 17267584
12. Efficient adenovirus vector-mediated PPAR gamma gene transfer into mouse embryoid bodies promotes adipocyte differentiation. Tashiro K, Kawabata K, Sakurai H, Kurachi S, Sakurai F, Yamanishi K, Mizuguchi H, J Gene Med 2008 10 5 498 507 10.1002/jgm.1171 18278825
13. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Akimoto T, Kusano E, Inaba T, Iimura O, Takahashi H, Ikeda H, Ito C, Ando Y, Ozawa K, Asano Y, Kidney Int 2000 58 1 269 282 10.1046/j.1523-1755.2000.00162.x 10886572
14. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Tsao PN, Su YN, Li H, Huang PH, Chien CT, Lai YL, Lee CN, Chen CA, Cheng WF, Wei SC, Am J Respir Crit Care Med 2004 169 4 505 511 10.1164/rccm.200306-774OC 14644931
15. American Heart Association, Heart Disease and Stroke Statistics-2004 Update Dallas, TX: American Heart Association 2004
16. Smooth muscle cell proliferation and restenosis after stand alone coronary excimer laser angioplasty. Karsch KR, Haase KK, Wehrmann M, Hassenstein S, Hanke H, J Am Coll Cardiol 1991 17 991 994 10.1016/0735-1097(91)90886-E 1999639
17. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA, Am J Physiol 1993 265 4 726 732
18. Rosiglitazone Evaluated for Cardiovascular Outcomes-An Interim Analysis. Home PD, Phil D, Pocock SJ, Henning B-N, Ramón G, Markolf H, Jones NP, Michel K, John JV MM, N Engl J Med 2007 357 28 38 10.1056/NEJMoa073394 17551159
19. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lago RM, Singh PP, Nesto RW, N Engl J Med 2007 356 2457 2471 10.1056/NEJMoa072761 17517853
20. Rosiglitazone evaluated for cardiovascular outcomes in oral agentcombination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.; RECORD Study Team. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, Lancet 2009 373 9681 2125 2135 10.1016/S0140-6736(09)60953-3 19501900
21. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Nissen SE, Kathy W, N Engl J Med 2007 356 24 2457 2471 10.1056/NEJMoa072761 17517853
22. Long-term risk of cardiovascular events with rosiglitazone, a meta-analysis. Sonal S, Loke YK, Furberg CD, JAMA 2007 298 10 1189 1195 10.1001/jama.298.10.1189 17848653
23. The ascochlorin derivative, AS-6, inhibits TNF-alpha-induced adhesion molecule and chemokine expression in rat vascular smooth muscle cells. Park KG, Lee KM, Chang YC, Magae J, Ando K, Kim KB, Kim YN, Kim HS, Park JY, Lee KU, Lee IK, Life Sci 2006 80 2 120 126 10.1016/j.lfs.2006.08.030 16989870
24. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada K, Circ Res 2002 91 5 427 433 10.1161/01.RES.0000031271.20771.4F 12215492
25. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA, J Clin Invest 1996 98 8 1897 1905 10.1172/JCI118991 8878442
26. PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL, Am J Physiol Heart Circ Physiol 2006 290 1 390 H397 16155101
27. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1 S transition in vascular smooth muscle cells. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE, J Biol Chem 2000 275 29 22435 22441 10.1074/jbc.M910452199 10801895
28. Peroxisome proliferator-activated receptor gamma ligand-mediated apoptosis of hepatocellular carcinoma cells depends upon modulation of PI3Kinase pathway independent of Akt. Mishra P, Paramasivam SK, Thylur RP, Rana A, Rana B, J Mol Signal 2010 5 20 10.1186/1750-2187-5-20 21144036
29. Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells. Goetze S, Kim S, Xi XP, Graf K, Yang DC, Fleck E, Meehan WP, Hsueh WA, Law RE, J Cardiovasc Pharmacol 2000 35 5 749 757 10.1097/00005344-200005000-00011 10813377
30. 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. Takeda K, Ichiki T, Tokunou T, Iino N, Takeshita A, J Biol Chem 2001 276 52 48950 48955 10.1074/jbc.M108722200 11687581
31. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Duan SZ, Usher MG, Mortensen RM, Circ Res 2008 102 3 283 294 10.1161/CIRCRESAHA.107.164384 18276926
32. Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways. Cersosimo E, Xu X, Musi N, Am J Physiol Cell Physiol 2012 302 4 652 657 10.1152/ajpcell.00022.2011
33. A prospective, multicenter, randomized trial to a ssess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, Tamita K, Yamamuro A, Sakanoue Y, Ito A, Yanagi S, Shimeno K, Waseda K, Yamasaki M, Fitzgerald PJ, Ikeno F, Honda Y, Yoshiyama M, Yoshikawa J, JACC Cardiovasc Interv 2009 2 6 524 531 10.1016/j.jcin.2009.04.007 19539256
34. Principles of CDK regulation. Morgan DO, Nature 1995 374 6518 131 134 10.1038/374131a0 7877684
35. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-γ: therapeutic implications for cardiovascular diseases. Florence G, Dennis B, PPAR Res 2008 2008 429123 18288288
36. Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides. Santucci MA, Mercatali L, Brusa G, Pattacini L, Barbieri E, Perocco P, Environ Mol Mutagen 2003 41 5 315 321 10.1002/em.10162 12802801
37. Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. Kim EJ, Park KS, Chung SY, Sheen YY, Moon DC, Song YS, Kim KS, Song S, Yun YP, Lee MK, Oh KW, Yoon DY, Hong JT, J Pharmacol Exp Ther 2003 307 2 505 517 10.1124/jpet.103.053876 12966153
38. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. Strakova N, Ehrmann J, Dzubak P, Bouchal J, Kolar Z, J Pharmacol Exp Ther 2004 309 3 1239 1247 10.1124/jpet.103.063438 14988421
39. Hemin inhibits hypertensive rat vascular smooth muscle cell proliferation through regulation of cyclin D and p21. Jeon EM, Choi HC, Lee KY, Chang KC, Kang YJ, Arch Pharm Res 2009 32 3 375 382 10.1007/s12272-009-1310-2 19387581
40. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Bruemmer D, Yin F, Liu J, Berger JP, Sakai T, Blaschke F, Fleck E, Van Herle AJ, Forman BM, Law RE, Circ Res 2003 93 4 38 e47 10.1161/01.RES.0000088344.15288.E6 12881480
41. Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism. Redondo S, Ruiz E, Santos-Gallego CG, Padilla E, Tejerina T, Diabetes 2005 54 3 811 817 10.2337/diabetes.54.3.811 15734860
42. Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. Yoo J, Ghiassi M, Jirmanova L, Balliet AG, Hoffman B, Fornace AJ Jr, Liebermann DA, Bottinger EP, Roberts AB, J Biol Chem 2003 278 44 43001 43007 10.1074/jbc.M307869200 12933797
43. Bcl-2 family members and apoptosis, taken to heart. Gustafsson AB, Gottlieb RA, Am J Physiol Cell Physiol 2007 292 1 45 C51 16943242
44. Opposing actions of rosiglitazone and resveratrol on mineralization in human vascular smooth muscle cells. Bruedigam C, Eijken M, Koedam M, Chiba H, Van Leeuwen JP, J Mol Cell Cardiol 2011 51 5 862 871 10.1016/j.yjmcc.2011.07.020 21816156